Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Human Vaccines & Immunotherapeutics|October 31, 2023
Preclinical support for tumor protein D52 as a cancer vaccine antigenRobert K BrightUltrasound in Medicine & Biology|October 10, 2024
Focused Ultrasound in Cancer Immunotherapy: A Review of Mechanisms and ApplicationsSadman Labib, Robert K Bright, Jingfei LiuInternational Reviews of Immunology|September 10, 2003
Tumor-associated antigens: from discovery to immunityJennifer D Lewis, Brian D Reilly, Robert K BrightHuman Vaccines & Immunotherapeutics|September 7, 2022
Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotypeC Riccay Elizondo, Jennifer D Bright, Robert K BrightHuman Vaccines & Immunotherapeutics|December 9, 2014
Overexpressed oncogenic tumor-self antigensRobert K Bright, Jennifer D Bright, Jennifer A ByrneTumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|May 7, 2014
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?Jennifer A Byrne, Sarah Frost, Yuyan Chen, et al.Journal of Translational Medicine|July 31, 2004
Cancer immunotherapy: avoiding the road to perditionMaurizio Chiriva-Internati, Fabio Grizzi, Robert K Bright, et al.Cancer Research|April 5, 2005
Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastasesJennifer D Lewis, Michael H Shearer, Ronald C Kennedy, et al.Oncoimmunology|September 28, 2013
Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigenJennifer D Bright, Heather N Schultz, Jennifer A Byrne, et al.Human Vaccines & Immunotherapeutics|November 27, 2019
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52C Riccay Elizondo, Jennifer D Bright, Jennifer A Byrne, et al.Pageof 4